II Studio / Shutterstock.com
24 July 2019AmericasRory O'Neill
Gilead licenses HIV injections for $25m
Gilead has obtained exclusive worldwide rights to market a long-acting injectable HIV product based on Durect Corporation’s Saber technology.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
9 May 2019 A generic version of Gilead’s Truvada will hit the market in 2020, a year earlier than expected.
Editor's picks
Editor's picks
Americas
9 May 2019 A generic version of Gilead’s Truvada will hit the market in 2020, a year earlier than expected.
Americas
9 May 2019 A generic version of Gilead’s Truvada will hit the market in 2020, a year earlier than expected.